Products: Cancer tests based on epigenetic biomarkers

Our products are cancer tests that detect characteristic epigenetic changes, i.e. DNA methylations, in cancer cells. These highly informative biomarkers, which we have identified and patented, are the basis of our research and development for further IVD tests.

Our goal is to develop tests for the diagnosis of cancer that are rapid, safe and non-invasive in application.

GynTect® – assay for cervical cancer screening

GynTect® enables the simple and reliable detection of methylated DNA regions in cervical scrapes. Methylation of GynTect® biomarkers occurs specifically in cervical cancer or its precursors, but not in samples from healthy women. Thus, GynTect® can help to clarify whether there is already a tissue alteration that needs to be treated.

Pipepline Products

Diagnostics of head and neck tumors

Worldwide, head and neck tumors are among the five most common cancers. In Germany, approximately 17,000 people are diagnosed with head and neck cancer each year. Head and neck tumors can often develop unnoticed for a long time, as it is difficult for those affected to recognize the signs themselves. However, the later the tumors are detected, the lower the chance of cure. Early diagnosis is therefore very important. The diagnosis of such a head and neck tumor by a specialist is not easy, because there are no early detection tests so far and accordingly no screening.

We are developing tests based on DNA methylation markers that detect cancer cells in the patient’s saliva. Our vision is to contribute significantly to a regulated screening program for head and neck cancer in the future.

Ovarian Cancer

Ovarian cancer (cancer of the ovary) is the second most common aggressive disease affecting the female reproductive organs, and its incidence increases with the age of the patients. Due to a lack of screening measures, the cancer is often detected very late, when a cure is no longer possible. In 2016, about 7,300 new cases and about 5,500 deaths were registered in Germany, according to the Robert Koch Institute, Germany.

A patient-friendly, safe screening test could help to significantly reduce the number of deaths caused by ovarian cancer.